射血分数降低心衰患者中醛固酮受体拮抗剂使用不足
该研究基于EMPHASIS-HF试验,按心衰病程将HFrEF患者分为<1年、1至<5年和≥5年三组,评估依普利酮的疗效与安全性。结果显示,随着病程延长,主要终点事件率升高,但依普利酮的获益在各病程组中一致,且病程最长组的绝对获益最大。
要点
- HFrEF病程越长,主要终点事件率越高,但依普利酮获益一致。
- 依普利酮在病程≥5年组绝对获益最大,NNT为10。
- 临床应重视醛固酮受体拮抗剂在HFrEF患者中的规范使用。
核心结论
- HFrEF病程较长的患者临床状况更差、事件率更高,但依普利酮的获益不受HFrEF病程影响。
研究设计与样本
- 基于EMPHASIS-HF试验,按HFrEF病程将患者分为<1年(975例)、1至<5年(769例)和≥5年(988例)三组,主要终点为心衰住院或心血管死亡复合终点,采用Cox回归模型校正预设预后变量。
主要发现
- 主要终点事件率(每100人年)随HFrEF病程增加:<1年组9.8(95%CI:8.4-11.4),1至<5年组13.5(95%CI:11.6-15.7),≥5年组17.6(95%CI:15.6-19.8)。
- 依普利酮对主要终点的HR在各病程组分别为:<1年组0.57(95%CI:0.42-0.79),1至<5年组0.81(95%CI:0.60-1.10),≥5年组0.61(95%CI:0.48-0.78);Pinteraction=0.24。
- 主要终点的NNT分别为:<1年组14,1至<5年组13,≥5年组10。
临床怎么用
- 对于HFrEF患者,无论病程长短,均应考虑使用依普利酮以降低心衰住院或心血管死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unknown how the efficacy and safety of mineralocorticoid receptor antagonists vary according to duration of heart failure with reduced ejection fraction (HFrEF). OBJECTIVES: In this study, we sought to evaluate the safety and efficacy of eplerenone according to duration of HFrEF. METHODS: In the EMPHASIS-HF trial, 3 patient groups were created according to HFrEF duration: <1 year, 1 to <5 years, and ≥5 years. The primary outcome was the composite of heart failure (HF) hospitalization or cardiovascular death. Outcomes were adjusted for prespecified prognostic variables and examined with the use of Cox regression models. RESULTS: The numbers of patients in each group were: 975, <1 year; 769, 1 to <5 years; and 988, ≥5 years. Patients with longer-standing HF were older and more frequently had cardiovascular and noncardiovascular comorbidities. The rate of the primary outcome (per 100 person-years) increased with HFrEF duration: 9.8 (95% CI: 8.4-11.4) for <1 year, 13.5 (95% CI: 11.6-15.7) for 1 to <5 years, and 17.6 (95% CI: 15.6-19.8) for ≥5 years. The benefits of eplerenone were consistent across HF duration: HRs for the primary outcome were 0.57 (95% CI: 0.42-0.79) for <1 year, 0.81 (95% CI: 0.60-1.10) for 1 to <5 years, and 0.61 (95% CI: 0.48-0.78) for ≥5 years; Pinteraction = 0.24. The absolute benefit was greatest in the longest-duration group: the number needed to treat for the primary outcome was 14 for <1 year, 13 for 1 to <5 years, and 10 for ≥5 years duration. CONCLUSIONS: Patients with longer-standing HFrEF had worse clinical status and a higher rate of events, but the benefit of eplerenone was consistent regardless of HFrEF duration. (A Comparison of Outcomes in Patients in NYHA Class II Heart Failure When Treated With Eplerenone or Placebo in Addition to Standard Heart Failure Medicines [EMPHASIS-HF]; NCT00232180).
引用
- Matsumoto, Kondo, Jhund, et al. Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2023. PMID: 37642608. doi:10.1016/j.jacc.2023.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。